Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.35 |
| ▸ | MTOR | P42345 | 4/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.35 |
| ▸ | ATR | Q13535 | 1/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2376507 | 0.93 | KEAP1 (0.39) | PIK3CAMTORPIK3CGNAMPT | |
| SCHEMBL2375778 | 0.93 | JAK2 (0.40) | DGAT1JAK2MAPK1NAMPT | |
| SCHEMBL2376202 | 0.92 | BRD4 (0.47) | BRD4PIK3CAMTOR | |
| SCHEMBL2377262 | 0.91 | CYP2C9 (0.37) | BRD4PIK3CAMTORPIK3CGATR | |
| SCHEMBL2377327 | 0.89 | BRD4 (0.42) | BRD4DGAT1MAPK1 | |
| SCHEMBL2376248 | 0.88 | JAK2 (0.42) | DGAT1JAK2MAPK1NAMPT | |
| SCHEMBL2379481 | 0.88 | JAK2 (0.45) | PIK3CAMTORPIK3CGATRJAK2 | |
| Hydrochloric Acid SCHEMBL2377246 | 0.87 | ABL1 (0.39) | BRD4PIK3CAPIK3CGDGAT1PIK3CD | |
| SCHEMBL2378940 | 0.86 | KDM4E (0.43) | BRD4PIK3CAMTORNAMPT | |
| SCHEMBL2378441 | 0.86 | DGAT1 (0.32) | PIK3CAPIK3CGDGAT1JAK2PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2373653-A1 | PYRROLOPYRAZINYL UREA KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2011-10-12 | — | — | EP | disclosed |
| US-8012974-B2 | Pyrrolopyrazinyl urea kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2011-09-06 | — | — | US | disclosed |
| WO-2010063634-A1 | PYRROLOPYRAZINYL UREA KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-06-10 | — | — | WO | disclosed |
| US-20100144745-A1 | Pyrrolopyrazinyl Urea Kinase Inhibitors | ROCHE PALO ALTO LLC | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144745-A1 | Pyrrolopyrazinyl Urea Kinase Inhibitors | JAK1, JAK3, ULK3 | BRD4 407/4885PIK3CA 563/4885MTOR 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.